<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Risk Management Plan - 100-005-RMP-001</title>
    <link rel="stylesheet" href="../../assets/css/summed-medtech-docs.css">
    <style>
        @media print {
            body {
                -webkit-print-color-adjust: exact;
                print-color-adjust: exact;
            }

            .page-break {
                page-break-after: always;
            }
        }

        .doc-info-table,
        .signature-table,
        .revision-table,
        .data-table {
            width: 100%;
            table-layout: auto;
            max-width: 100%;
        }

        .risk-matrix-table {
            font-size: 10pt;
            border-collapse: collapse;
        }

        .risk-matrix-table th,
        .risk-matrix-table td {
            border: 1px solid #003366;
            padding: 8px;
            text-align: center;
            vertical-align: middle;
        }

        .risk-matrix-table th {
            background-color: #003366;
            color: white;
            font-weight: bold;
        }

        .risk-cell-a {
            background-color: #d4edda;
        }

        .risk-cell-r {
            background-color: #fff3cd;
        }

        .risk-cell-n {
            background-color: #f8d7da;
        }

        .lifecycle-table {
            font-size: 9pt;
        }

        .lifecycle-table th,
        .lifecycle-table td {
            padding: 6px;
            vertical-align: top;
        }

        .team-table {
            font-size: 8pt;
        }

        .team-table th,
        .team-table td {
            padding: 5px;
            vertical-align: top;
        }

        .figure-container {
            text-align: center;
            margin: 20px 0;
        }

        .figure-container img {
            max-width: 100%;
            height: auto;
            border: 1px solid #ccc;
        }

        .figure-caption {
            font-size: 9pt;
            color: #666;
            margin-top: 8px;
        }
    </style>
</head>

<body>
    <div class="a4-container">

        <div class="header-section">
            <img src="../../assets/images/Summed logo.png" alt="Summed Medtech 森迈医疗" class="company-logo"
                style="width: 80% !important; max-width: 300px !important; height: auto !important;">
            <div class="document-meta">
                <div><strong>Document No.:</strong> 100-005-RMP-001</div>
                <div><strong>Revision:</strong> 1.0</div>
            </div>
        </div>

        <h1>Risk Management Plan (RMP)</h1>
        <h2>Auto-Injector Risk Management Plan</h2>

        <table class="doc-info-table">
            <tr>
                <td width="25%"><strong>Document No.:</strong></td>
                <td colspan="3">100-005-RMP-001</td>
            </tr>
            <tr>
                <td><strong>Revision:</strong></td>
                <td>1.0</td>
                <td><strong>Effective Date:</strong></td>
                <td>2024-07-18</td>
            </tr>
            <tr>
                <td><strong>Prepared by:</strong></td>
                <td colspan="3">Kayla Li</td>
            </tr>
        </table>

        <!-- Signature Table - Horizontal Format -->
        <table class="signature-table">
            <tr>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Kayla Li</div>
                        <div class="signature-title">QA Manager</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Prepared by</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Kevin Lo</div>
                        <div class="signature-title">RD Director</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Reviewed by</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Andy Tsai</div>
                        <div class="signature-title">General Manager</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Approved by</div>
                    </div>
                </td>
            </tr>
        </table>

        <h3>Revision History</h3>
        <table class="revision-table">
            <thead>
                <tr>
                    <th width="15%">Revision Level</th>
                    <th width="20%">Date of Revision</th>
                    <th width="65%">Revision Description</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>1.0</td>
                    <td>2024-07-18</td>
                    <td>New file</td>
                </tr>
            </tbody>
        </table>

        <div class="page-break"></div>

        <h2>1. Product Introduction</h2>

        <h3>1.1 Product Name and Model</h3>
        <table class="data-table table-2col">
            <tbody>
                <tr>
                    <td><strong>Product Name:</strong></td>
                    <td>Auto-Injector</td>
                </tr>
                <tr>
                    <td><strong>Product Model:</strong></td>
                    <td>SM-AISI104, SM-AISI105</td>
                </tr>
                <tr>
                    <td><strong>Product Specification:</strong></td>
                    <td>0.30 mL, 0.15 mL</td>
                </tr>
            </tbody>
        </table>

        <h3>1.2 Intended Use and Target Population</h3>

        <h4>1.2.1 Intended Use</h4>
        <p>For use with Epinephrine injection (pre-filled) (0.3 mg/0.3 mL, 0.15 mg/0.3 mL) for drug delivery
            (intramuscular
            injection). For single patient or individual single use only.</p>

        <h4>1.2.2 Target Population</h4>
        <table class="data-table table-2col">
            <tbody>
                <tr>
                    <td><strong>Adult Model:</strong></td>
                    <td>Patients with body weight ≥ 30 kg</td>
                </tr>
                <tr>
                    <td><strong>Pediatric Model:</strong></td>
                    <td>Patients with body weight 15-30 kg</td>
                </tr>
            </tbody>
        </table>

        <div class="page-break"></div>

        <h2>2. Risk Management Scope</h2>

        <h3>2.1 Life Cycle Coverage</h3>
        <p>The Auto-Injector Risk Management Plan covers all stages of the life cycle, including design and development
            planning, design and development, design changes, models, pre-clinical evaluation, clinical evaluation,
            manufacturing, sales, use, after-sales service and disposal.</p>

        <div class="figure-container">
            <img src="../../assets/images/100-005-RMP-2-1.png" alt="Risk Management Process Flow">
            <p class="figure-caption">Figure 1: Risk Management Process Flow</p>
        </div>

        <h3>2.2 Risk Management Process (Planned Risk Management Activities)</h3>
        <p>According to ISO 14971:2019 Figure 1, Summed has established and maintains an effective risk management
            process, as shown below.</p>

        <div class="figure-container">
            <img src="../../assets/images/100-005-RMP-2-2.png" alt="Risk Management Activities Timeline">
            <p class="figure-caption">Figure 2: Risk Management Activities Throughout Lifecycle</p>
        </div>

        <div class="page-break"></div>

        <h2>3. Assignment of Responsibilities and Authority</h2>
        <p>Personnel performing risk management activities/tasks shall have the education, training, skills and
            experience
            appropriate to the activities/tasks assigned to them. These personnel should have knowledge and experience
            of
            specific (or similar) medical devices and their use, the technologies involved or the risk management
            techniques
            employed. The following table summarizes the personnel and knowledge/experience for this risk management.
        </p>

        <h3>Management Representative</h3>
        <table class="data-table team-table">
            <thead>
                <tr>
                    <th width="15%">Role</th>
                    <th width="10%">Name</th>
                    <th width="25%">Qualifications</th>
                    <th width="50%">Allocation of Risk Management Activities</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Project Leader</td>
                    <td>Kevin Lo</td>
                    <td>Education: Master's<br>Major: Biomedical Engineering<br>Work Experience: 20 years in Class II
                        and
                        III medical device R&D, responsible for product development, technical documentation, risk
                        management, etc.<br>Training: ISO13485, ISO14971, ISO11135 sterilization validation</td>
                    <td>Responsible for coordinating resources required for risk management activities.</td>
                </tr>
                <tr>
                    <td>Quality Dept.</td>
                    <td>Kayla Li</td>
                    <td>Education: Master's<br>Major: Management Science<br>Work Experience: 10+ years in quality
                        management, familiar with QMS requirements<br>Training: ISO13485 internal auditor</td>
                    <td>Responsible for leading risk management throughout the product lifecycle. Specifically:<br>
                        1. Formulate pre-market and post-market risk management plans<br>
                        2. Collect risk inputs<br>
                        3. Lead preliminary hazard analysis<br>
                        4. Write PHA reports and risk management reports<br>
                        5. Participate in DMFEA, PFMEA, UFMEA discussions and approve risk management documents<br>
                        6. Organize pre-market risk management review<br>
                        7. Lead post-market risk management</td>
                </tr>
                <tr>
                    <td>Production Dept.</td>
                    <td>Gao Zhangyun</td>
                    <td>Education: Master's<br>Major: Materials Engineering<br>Work Experience: 8 years in production
                        and
                        process, 5 years in Class II and III medical devices, responsible for R&D, process and
                        production,
                        familiar with medical device full lifecycle<br>Training: ISO14971 risk management training</td>
                    <td>1. Responsible for leading PFMEA discussions and writing PFMEA reports<br>
                        2. Participate in PHA, DFMEA, UFMEA, risk management report discussions and risk management
                        review;
                        approve risk management documents<br>
                        3. Production anomaly feedback and improvement, product hazard confirmation</td>
                </tr>
                <tr>
                    <td>Marketing/Sales</td>
                    <td>Doris Chang</td>
                    <td>Education: Clinical Nutrition<br>Work Experience: 2 years in chemical reagent suppliers, 4 years
                        in
                        professional injection pharmaceuticals from raw materials to preparations, 2 years in
                        biopharmaceutical CDMO (monoclonal antibodies, vaccines, ADC), 2 years in drug delivery device
                        sales<br>Training: ISO13485 QMS, ISO14971 risk management training, GMP, FDA, TFDA audit
                        experience
                    </td>
                    <td>1. Responsible for leading UFMEA discussions and writing UFMEA reports<br>
                        2. Participate in PHA, DFMEA, PFMEA, risk management report discussions and risk management
                        review<br>
                        3. Approve risk management documents</td>
                </tr>
                <tr>
                    <td>Regulatory/Registration</td>
                    <td>Grace Xue</td>
                    <td>Education: PhD<br>Major: Biochemistry and Molecular Biology<br>Work Experience: Nearly 15 years
                        in
                        pharmaceutical R&D and drug-device combination product regulatory management<br>Training:
                        Medical
                        device clinical practice GCP training and ISO14971 risk management training</td>
                    <td>Participate in PHA, DFMEA, PFMEA, UFMEA and risk management report discussions and risk
                        management
                        review, and approve risk management documents.</td>
                </tr>
            </tbody>
        </table>

        <div class="page-break"></div>

        <h2>4. Risk Acceptance Criteria</h2>

        <h3>4.1 Risk Severity Level Classification</h3>
        <table class="data-table table-3col">
            <thead>
                <tr>
                    <th>Level Name</th>
                    <th>Code</th>
                    <th>Definition</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Catastrophic</td>
                    <td>5</td>
                    <td>Results in patient death</td>
                </tr>
                <tr>
                    <td>Critical</td>
                    <td>4</td>
                    <td>Results in permanent injury or life-threatening injury</td>
                </tr>
                <tr>
                    <td>Serious</td>
                    <td>3</td>
                    <td>Results in injury or damage requiring professional medical intervention</td>
                </tr>
                <tr>
                    <td>Minor</td>
                    <td>2</td>
                    <td>Results in injury or damage not requiring professional medical intervention</td>
                </tr>
                <tr>
                    <td>Negligible</td>
                    <td>1</td>
                    <td>Inconvenience or temporary discomfort</td>
                </tr>
            </tbody>
        </table>

        <h3>4.2 Risk Probability Level</h3>
        <table class="data-table table-3col">
            <thead>
                <tr>
                    <th>Level Name</th>
                    <th>Code</th>
                    <th>Frequency (per year)</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Frequent</td>
                    <td>5</td>
                    <td>≥ 10<sup>-3</sup></td>
                </tr>
                <tr>
                    <td>Probable</td>
                    <td>4</td>
                    <td>10<sup>-3</sup> > and ≥ 10<sup>-4</sup></td>
                </tr>
                <tr>
                    <td>Occasional</td>
                    <td>3</td>
                    <td>10<sup>-4</sup> > and ≥ 10<sup>-5</sup></td>
                </tr>
                <tr>
                    <td>Remote</td>
                    <td>2</td>
                    <td>10<sup>-5</sup> > and ≥ 10<sup>-6</sup></td>
                </tr>
                <tr>
                    <td>Improbable</td>
                    <td>1</td>
                    <td>
                        < 10<sup>-6</sup>
                    </td>
                </tr>
            </tbody>
        </table>

        <p><em>Note: Frequency refers to the number of events occurring or expected to occur per device per year.</em>
        </p>

        <h3>4.3 Risk Acceptability Criteria</h3>
        <table class="risk-matrix-table">
            <thead>
                <tr>
                    <th rowspan="3">Probability<br>Level (PL)</th>
                    <th rowspan="3">Code</th>
                    <th colspan="5">Severity Level (SL)</th>
                </tr>
                <tr>
                    <th>Negligible</th>
                    <th>Minor</th>
                    <th>Serious</th>
                    <th>Critical</th>
                    <th>Catastrophic</th>
                </tr>
                <tr>
                    <th>1</th>
                    <th>2</th>
                    <th>3</th>
                    <th>4</th>
                    <th>5</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Frequent</td>
                    <td>5</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                </tr>
                <tr>
                    <td>Probable</td>
                    <td>4</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                </tr>
                <tr>
                    <td>Occasional</td>
                    <td>3</td>
                    <td class="risk-cell-a">A</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-n">N</td>
                    <td class="risk-cell-n">N</td>
                </tr>
                <tr>
                    <td>Remote</td>
                    <td>2</td>
                    <td class="risk-cell-a">A</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-n">N</td>
                </tr>
                <tr>
                    <td>Improbable</td>
                    <td>1</td>
                    <td class="risk-cell-a">A</td>
                    <td class="risk-cell-a">A</td>
                    <td class="risk-cell-a">A</td>
                    <td class="risk-cell-r">R</td>
                    <td class="risk-cell-r">R</td>
                </tr>
            </tbody>
        </table>

        <p><strong>Explanation:</strong> A = Acceptable risk, R = Reasonably feasible reduction of risk, N =
            Unacceptable
            risk</p>

        <p>For each risk level, the acceptable risk (SL × PL) should be below 3 (severity ≤ 3), which is acceptable for
            our
            product. The (SL × PL) should be below 9 (severity ≤ 9), which is reasonably feasible reduction of risk for
            our
            product. In other words, a risk level higher than 10 is unacceptable. If the risk cannot be reduced to an
            acceptable range through feasible risk control measures, we need to confirm whether the benefits outweigh
            the
            risks.</p>

        <div class="page-break"></div>

        <h3>4.4 Risk Analysis</h3>
        <p><strong>Purpose:</strong> To systematically identify known and foreseeable hazards associated with medical
            devices.</p>

        <h4>Risk Management Method</h4>
        <p>A 1-5 point scale is used to score the occurrence (O), severity (S) and detection (D) of each failure mode,
            and
            calculate the Risk Priority Number (RPN):</p>
        <p style="text-align: center; font-size: 14pt; font-weight: bold;">RPN = O × S × D</p>

        <ul>
            <li><strong>RPN ≥ 27:</strong> Risk reduction measures must be taken</li>
            <li><strong>RPN < 27:</strong> Optimization as applicable, not mandatory</li>
        </ul>

        <h4>4.4.1 Information Collection and Lifecycle Stages</h4>
        <p>Risk analysis should be based on qualitative and quantitative information collected from the following
            lifecycle
            stages:</p>

        <table class="data-table lifecycle-table">
            <thead>
                <tr>
                    <th width="20%">Lifecycle Stage</th>
                    <th width="50%">Information & Activities to Collect (Risk Analysis Input)</th>
                    <th width="30%">Information/Data Source</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Concept & Design Input</td>
                    <td>• Intended use, performance requirements, user characteristics (age, ability, education), use
                        environment<br>
                        • Applicable regulations, standards and scientific literature</td>
                    <td>• Product Requirement Specification (PRS)<br>
                        • Regulations, ISO 11608</td>
                </tr>
                <tr>
                    <td>Design & Development</td>
                    <td>• Design drawings, material selection, working principle analysis<br>
                        • Preliminary Hazard Analysis (PHA): Identify significant hazards based on design concept<br>
                        • Design FMEA: Analyze potential failure modes of components, subsystems and systems<br>
                        • Usability engineering files: User interface, task analysis, known use errors</td>
                    <td>• Design reviews<br>
                        • dFMEA report</td>
                </tr>
                <tr>
                    <td>Production & Manufacturing</td>
                    <td>• Process validation protocols and reports (IQ/OQ/PQ)<br>
                        • In-line quality control data (e.g., dose accuracy tests, functional tests)<br>
                        • Product identification and traceability records<br>
                        • Process FMEA (pFMEA): Analyze defects that may be introduced in the production process</td>
                    <td>• Validation reports<br>
                        • Inspection records, statistical process control (SPC) data<br>
                        • PFMEA report</td>
                </tr>
                <tr>
                    <td>Packaging, Transport & Storage</td>
                    <td>• Packaging validation reports (simulated transport, drop, vibration tests)<br>
                        • Storage condition stability data</td>
                    <td>• Packaging validation protocols and reports<br>
                        • Real-time/accelerated aging study reports</td>
                </tr>
                <tr>
                    <td>Post-Market Stage</td>
                    <td>• Adverse event reports and trend analysis<br>
                        • After-sales service data (maintenance, inquiries)</td>
                    <td>• Adverse event monitoring databases (e.g., EUDAMED)</td>
                </tr>
            </tbody>
        </table>

        <div class="page-break"></div>

        <h2>5. Overall Residual Risk</h2>
        <p>The method for evaluating overall residual risk and the risk acceptability criteria for overall residual risk
            will be assessed after all risk control measures have been implemented and verified, considering the
            contribution of all residual risks.</p>

        <p>If the overall residual risk is considered unacceptable relative to the expected benefits, additional risk
            control measures or modifications to the medical device or its intended use will be considered.</p>

        <p>Our medical device should fully meet the acceptability criteria for overall residual risk.</p>

        <p>The acceptability criteria for overall residual risk will be judged by experts with application knowledge and
            clinical expertise.</p>

        <p>To define the acceptability criteria for overall residual risk, the following inputs and considerations
            should be
            considered:</p>

        <h3>5.1 Considerations for Overall Residual Risk Assessment</h3>
        <ol>
            <li>Different event sequences may lead to different hazardous situations and risks.</li>
            <li>Different hazardous situations may produce specific harm.</li>
            <li>Risk control measures applicable to individual risks may lead to conflicting requirements, thereby
                increasing overall residual risk.</li>
            <li>Warning considerations alone may adequately reduce individual risks. However, excessive warnings may
                confuse
                users, thereby reducing the effectiveness of individual warnings. Analysis may be needed to determine
                whether there is over-reliance on warnings and whether this over-reliance affects risk reduction and
                overall
                residual risk.</li>
            <li>A comprehensive review of all instructions for use of the medical device may reveal that these
                instructions
                are inconsistent or too difficult to follow.</li>
            <li>The results of design verification, usability studies, clinical evaluation, pre-clinical evaluation and
                clinical investigations can provide useful information about overall residual risk.</li>
            <li>All benefit-risk analyses of individual risks should be considered.</li>
            <li>When there are trade-offs between risks in the risk analysis, the impact on overall residual risk should
                be
                analyzed with particular care.</li>
        </ol>

        <h3>5.2 Methods for Evaluating Overall Residual Risk</h3>
        <p>The method for evaluating overall residual risk can take the following approaches:</p>

        <ol type="a">
            <li><strong>Benefit-Risk Comparison:</strong> Weigh the benefits related to the intended use of the medical
                device against the overall residual risk. This assessment will consider knowledge of indications,
                techniques
                and the latest state-of-the-art in the medical field, as well as the availability of alternative medical
                devices or treatments.</li>
            <li><strong>Visual Representation:</strong> Visual representation of residual risks may be useful. Each
                individual residual risk will be displayed in the following risk matrix. If many risks are located in
                the
                higher severity or higher probability regions of the risk matrix, the distribution of risks may indicate
                that the overall residual risk may be unacceptable, even if each individual risk has been judged
                acceptable.
            </li>
            <li><strong>Comparison with Similar Devices:</strong> Compare the residual risks caused by our medical
                device
                with corresponding risks of similar medical devices on the market. Considering differences in intended
                use,
                the residual risks caused by the medical device can be individually compared with the risks of similar
                medical devices.</li>
            <li><strong>Expert Assessment:</strong> Expert-supported assessment of overall residual risk related to the
                expected benefits of using the medical device under consideration.</li>
            <li><strong>Further Investigation:</strong> Although at this point all individual risks should have been
                identified, controlled and judged acceptable, further investigation of certain risks may be appropriate
                as a
                result of the overall residual risk assessment, especially those that are nearly unacceptable.</li>
            <li><strong>Risk Interdependency:</strong> Further investigation is also appropriate when certain risks are
                interdependent with their causes or the risk control measures employed. The effectiveness of risk
                control
                should be verified not only individually but also in combination with other risk control measures.
                Failure
                Mode and Effects Analysis (FMEA) and Event Tree Analysis (ETA) can be useful tools for discovering
                relationships between risks and risk control measures.</li>
        </ol>

        <div class="page-break"></div>

        <h2>6. Implementation and Effectiveness Verification of Risk Control Measures</h2>
        <p>All risk control measures capable of reducing risk shall be verified. Verification will be summarized in the
            risk
            management report. Verification of risk control measures can be conducted as part of design/development
            verification and process verification. However, verification of the effectiveness of risk control measures
            can
            be performed as part of design/development verification.</p>

        <h2>7. Post-Market Product Information Collection and Review</h2>
        <p>Post-production information will be collected in accordance with product quality monitoring, medical device
            reporting, post-market information collection and monitoring (PMS), and post-market clinical follow-up
            (PMCF) in
            compliance with ISO 13485:2016 Section 8.2 "Monitoring and Measurement".</p>

        <p>In the risk management process, we use pre-clinical data results to identify device-related hazards and
            verify
            the effectiveness of risk control measures, and then through continuous collection, analysis and evaluation
            of
            clinical data, including clinical benefits from systematic clinical evaluation, to verify device performance
            and
            safety as part of the risk management report input.</p>

        <div class="page-break"></div>

        <h2>8. Appendix</h2>

        <h3>Appendix A: Post-Market Risk Management Activities</h3>

        <table class="data-table table-5col">
            <thead>
                <tr>
                    <th width="20%">Activity Content</th>
                    <th width="25%">Evaluation Points</th>
                    <th width="25%">Deliverables</th>
                    <th width="15%">Responsible Dept.</th>
                    <th width="15%">Completion Timeline</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Product Design/Process Changes</td>
                    <td>1. Whether new hazards are introduced<br>
                        2. Whether risk estimation is acceptable<br>
                        3. Verification of effectiveness of control measures</td>
                    <td>Change records, risk document updates</td>
                    <td>RD/PD/RA</td>
                    <td>Before change implementation</td>
                </tr>
                <tr>
                    <td>Standard/Regulation Updates</td>
                    <td>ISO 11608, ISO 14971 and other related standard dynamics</td>
                    <td>Regulatory compliance evaluation report</td>
                    <td>RA</td>
                    <td>Before standard implementation</td>
                </tr>
                <tr>
                    <td>Market Use Information</td>
                    <td>Customer complaints, adverse events, use error cases</td>
                    <td>Annual use information analysis report</td>
                    <td>BD/QA</td>
                    <td>Annually</td>
                </tr>
                <tr>
                    <td>Production Process Stability</td>
                    <td>Key process parameters (SPC), PFMEA updates</td>
                    <td>Process anomaly handling report</td>
                    <td>PD</td>
                    <td>Within 72 hours after anomaly occurrence</td>
                </tr>
            </tbody>
        </table>

        <div class="page-break"></div>

        <!-- Additional Reviewer Signatures -->
        <h2>Additional Reviewers</h2>
        <table class="signature-table">
            <tr>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Grace Xue</div>
                        <div class="signature-title">RA Director</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Reviewed by</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Doris Chang</div>
                        <div class="signature-title">BD Manager</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Reviewed by</div>
                    </div>
                </td>
                <td>
                    <div class="signature-block">
                        <div class="signature-name">Gao Zhangyun</div>
                        <div class="signature-title">Production Supervisor</div>
                        <div class="signature-line"></div>
                        <div class="signature-label">Reviewed by</div>
                    </div>
                </td>
            </tr>
        </table>

        <div class="footer">
            <p>Summed Medtech 森迈医疗 | Document No.: 100-005-RMP-001 | Revision: 1.0</p>
        </div>

    </div>
</body>

</html>